There is no single CA-125 level that confirms cancer. The widely used threshold is 35 units per milliliter (U/mL), above which results are considered abnormal. But an elevated reading can come from many conditions that have nothing to do with cancer, and some women with early-stage ovarian cancer have levels that fall well within the normal range. Understanding what this number actually means, and what it doesn’t, can save you a lot of unnecessary worry.
The Standard 35 U/mL Threshold
CA-125 is a protein produced by certain cells in the body, particularly cells lining the ovaries, uterus, and fallopian tubes. When those cells are irritated, inflamed, or growing abnormally, they release more CA-125 into the bloodstream. Labs generally flag any result above 35 U/mL as irregular.
That cutoff is a starting point, not a diagnosis. When used alone with a fixed 35 U/mL threshold, the test catches roughly 69% of ovarian cancers and correctly rules out about 83% of non-cancerous cases. That means nearly a third of ovarian cancers don’t push the number above 35, and a meaningful number of women above 35 turn out to have something benign. The American College of Obstetricians and Gynecologists has noted that fixed CA-125 cutoff values for early-stage cancer detection have poor sensitivity and specificity, and that using CA-125 alone has not been proven to reduce ovarian cancer deaths.
Why Menopausal Status Changes the Cutoff
Your hormonal stage significantly affects what counts as a normal CA-125 reading. A large prospective screening study of high-risk women found that premenopausal women naturally run higher and need a different benchmark:
- Postmenopausal women: 35 U/mL (the standard cutoff)
- Premenopausal women: 50 U/mL
- Premenopausal women on oral contraceptives: 40 U/mL
Using the standard 35 U/mL cutoff for a premenopausal woman leads to more false alarms. About 5.2% of premenopausal women in one population study had CA-125 levels above 35 without any malignancy. Menstrual timing also plays a role: CA-125 tends to rise around the time of your period and dip at midcycle. A single elevated reading in a premenopausal woman may simply reflect where she is in her cycle rather than anything dangerous.
Non-Cancer Causes of Elevated CA-125
Plenty of benign conditions push CA-125 above 35 U/mL, sometimes well above it. The protein is released whenever the tissue lining the abdomen and pelvis is inflamed or disrupted. Common culprits include:
- Endometriosis: one of the most frequent non-cancerous causes of moderately elevated CA-125
- Liver cirrhosis: can produce significantly high readings, especially when fluid accumulates in the abdomen
- Kidney disease: both chronic kidney failure and nephrotic syndrome are associated with elevated levels
- Pancreatitis: acute or chronic inflammation of the pancreas
- Pelvic inflammatory disease and uterine fibroids
- Ovarian hyperstimulation syndrome: sometimes seen during fertility treatment
Even conditions that seem unrelated to the reproductive system, like tuberculosis affecting the abdomen or severe liver failure, can send CA-125 readings climbing. This is why doctors never use an elevated number in isolation to diagnose ovarian cancer. Imaging, physical examination, and sometimes additional blood markers are part of the picture.
How Doctors Improve Accuracy
Because CA-125 alone misses too many cancers and flags too many benign conditions, clinicians often combine it with other tools. One approach is the Risk of Ovarian Malignancy Algorithm (ROMA), which pairs CA-125 with a second blood marker called HE4. In comparative studies, the ROMA index raised sensitivity to about 76% and pushed specificity to 100%, meaning it virtually eliminated false positives. That is a significant improvement over CA-125 on its own.
Another method tracks your CA-125 over time rather than relying on a single snapshot. The Risk of Ovarian Cancer Algorithm uses serial measurements and mathematical modeling to detect a trend. A rising trajectory, even if every individual reading falls below 35 U/mL, can be more informative than one high number. ACOG has noted this serial approach has a better positive predictive value than any fixed cutoff.
CA-125 Levels During Cancer Monitoring
Where CA-125 becomes most useful is after an ovarian cancer diagnosis, during treatment and follow-up. In this context, doctors are not trying to detect cancer for the first time. They are watching for changes from your personal baseline.
For women whose CA-125 normalized after initial treatment, the commonly accepted signal of recurrence is a doubling from the upper limit of normal (from 35 U/mL). For women whose levels never fully normalized, the benchmark is a doubling from whatever their lowest post-treatment level was. Research published in the Journal of Clinical Oncology found that a 100% relative increase from a patient’s lowest recorded level was a strong predictor of recurrence, with an odds ratio of nearly 24.
Even smaller absolute changes matter. An increase of just 5 U/mL from a patient’s baseline low was significantly associated with recurrence, and a rise of 10 U/mL was an even stronger signal. Combining both criteria (an absolute increase of more than 5 U/mL or a relative increase of more than 100%) correctly identified all patients with recurrent disease in one study while also correctly classifying over 94% of those who remained disease-free. These thresholds apply specifically to women who have already been treated for ovarian cancer, not to the general population.
CA-125 and Other Types of Cancer
Though CA-125 is most associated with ovarian cancer, it can also be elevated in cancers of the pancreas, lung, breast, uterus, colon, and stomach. The protein is not exclusive to ovarian tissue; any cancer that irritates the abdominal or chest lining can raise it. This is one more reason a high number alone does not point to a specific diagnosis. Doctors use the result alongside imaging, other tumor markers, and your symptoms to narrow the possibilities.
What an Elevated Result Actually Means for You
If your CA-125 comes back above 35 U/mL on a routine test, the most likely next step is further evaluation, not a cancer diagnosis. Your doctor will typically order a pelvic ultrasound and may repeat the blood test after a few weeks to see whether levels are rising, stable, or falling. Context matters enormously: a reading of 45 U/mL in a 30-year-old with known endometriosis carries a very different meaning than the same reading in a 65-year-old with a new pelvic mass on imaging.
The higher the level, the more concerning it becomes, but there is no magic number that separates cancer from everything else. Readings in the hundreds or thousands are more commonly associated with advanced ovarian cancer, but even very high levels can occasionally come from severe endometriosis or liver disease. The test is one piece of a larger puzzle, and its value depends heavily on who you are, what symptoms you have, and how the number changes over time.